Reports
Sale
Latin America Anti-Obesity Drugs Market Size, Share, Growth: By Drugs: Semaglutide, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide, Gelesis 100, Orlistat, Others; By Drug Class; By Mechanism of Action; By Route of Administration; By Prescription Type; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032
Latin America Anti-Obesity Drugs Market Outlook
The global anti-obesity drugs market size was valued at USD 2.5 billion in 2023, with Latin America holding a significant market share. It is expected to grow at a CAGR of 10.70% during the forecast period of 2024-2032. The market is poised to secure a value of USD 6.3 billion by 2032, driven by the rising prevalence of obesity among children and teenagers across the region.
Key Takeaways
- According to the report released by the United Nations, Overview of Food Security and Nutrition 2022, almost one-fourth (22.5%) of the Latin American population is unable to afford a healthy meal in comparison to the world approximately priced at USD 3.89 per person per day.
- The increasing prevalence of obesity due to the adaption of a sedentary lifestyle along with unhealthy dietary habits are significant factors driving the Latin America anti-obesity drugs market growth in the forecast period.
- The regional market is witnessing high incidence of anti-obesity drugs, which is likely to boost the market share in the forecast period. In February 2023, Tesofensine received positive opinions from Mexican Food and Drug Administration.
Latin America Anti-Obesity Drugs Market Analysis
Obesity is a growing problem globally and is significantly contributing to high rates of health issues. Therefore, battling this condition is a major necessity of the hour. The Latin American region is facing major health issues related to obesity among children, teenagers, and adults. In August 2023, UNICEF released a report which highlighted that more than 4 million children aged 5 years or less were overweight in Latin American and Caribbean region.
Latin America anti-obesity drugs market share is estimated to be influenced by the approval of drugs by regional regulatory authorities. For instance, in December 2019, Medix, a Mexican pharmaceutical company submitted a New Drug Application (NDA) to the Mexican Food and Drug Administration COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) for the approval of tesofensine (a monoamine uptake inhibitor), which can be used for treating obesity in patients. Tesofensine has demonstrated effective loss results in phase II studies in obese patients. After a long wait, on February 26, 2023, the tesofensine was provided a favourable opinion by the Mexican regulatory authority for the treatment of obese patients. Considering the efficacy provided by tesofensine in the clinical trial, a potential interest from both healthcare providers and patients is anticipated, propelling the market growth. The competitive landscape is also expected to be driven by the approval of tesofensine.
Latin America anti-obesity drugs market demand is likely to be propelled by the alarmingly increasing obesity rates. It has been highlighted that the current prevalence rate in Latin America is above the global average, and it has been rising over the last two decades at a sustained rate. Additionally, it contributes to various other health concerns such as hypertension, high cholesterol, diabetes, cardiovascular disease, and even cancer. Addressing obesity among people at early stages is a major precaution that can play a crucial role in timely treatments and overall increased the life expectancy of obese population in the region.
Latin America Anti-Obesity Drugs Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
| Market Breakup | Categories |
| Drugs | Semaglutide, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide, Gelesis 100, Orlistat, Phentermine, Methamphetamine, Tirzepatide |
| Drug Class | Amphetamine, GLP-1 receptor agonist, Lipase Inhibitor |
| Mechanism of Action | Centrally Acting Drugs, Peripherally Acting Drugs |
| Route of Administration | Oral, Subcutaneous |
| Prescription Type | Prescription Drugs, Over the Counter Drugs |
| Distribution Channel | Hospital Pharmacies, Drug Store & Retail Pharmacies, Online Pharmacies |
| Countries | Brazil, Argentina, Mexico, Others |
Latin America Anti-Obesity Drugs Market: Competitor Landscape
The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- VIVUS Inc.
- Pfizer, Inc.
- Novo Nordisk
- Bayer AG
- F Hoffmann-La-Roche
- Glaxosmithkline
- Arena Pharmaceuticals
- Eisai Co. Ltd
- Takeda Pharmaceutical Company
- Nalpropion Pharmaceuticals Inc
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drugs |
|
| Breakup by Drug Class |
|
| Breakup by Mechanism of Action |
|
| Breakup by Route of Administration |
|
| Breakup by Prescription Type |
|
| Breakup by Distribution Channe |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Latin America Anti-Obesity Drugs Market Overview
3.1 Latin America Anti-Obesity Drugs Market Historical Value (2017-2023)
3.2 Latin America Anti-Obesity Drugs Market Forecast Value (2024-2032)
4 Latin America Anti-Obesity Drugs Market Landscape*
4.1 Latin America Anti-Obesity Drugs Market: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Latin America Anti-Obesity Drugs Market: Product Landscape
4.2.1 Analysis by Product
4.2.2 Analysis by Material
4.2.3 Analysis by Type
5 Latin America Anti-Obesity Drugs Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Analysis
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Latin America Anti-Obesity Drugs Market Segmentation (2017-2032)
6.1 Latin America Anti-Obesity Drugs Market (2017-2032) by Drugs
6.1.1 Market Overview
6.1.2 Semaglutide
6.1.3 Phentermine/Topiramate
6.1.4 Naltrexone/Bupropion
6.1.5 Liraglutide
6.1.6 Gelesis 100
6.1.7 Orlistat
6.1.8 Phentermine
6.1.9 Methamphetamine
6.1.10 Tirzepatide
6.2 Latin America Anti-Obesity Drugs Market (2017-2032) by Drug Class
6.2.1 Market Overview
6.2.2 Amphetamine
6.2.3 GLP-1 receptor agonist
6.2.4 Lipase Inhibitor
6.3 Latin America Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
6.3.1 Market Overview
6.3.2 Centrally Acting Drugs
6.3.3 Peripherally Acting Drugs
6.4 Latin America Anti-Obesity Drugs Market (2017-2032) by Route of Administration
6.4.1 Market Overview
6.4.2 Oral
6.4.3 Subcutaneous
6.5 Latin America Anti-Obesity Drugs Market (2017-2032) by Prescription Type
6.5.1 Market Overview
6.5.2 Prescription Drugs
6.5.3 Over The Counter Drugs
6.6 Latin America Anti-Obesity Drugs Market (2017-2032) by Distribution Channel
6.6.1 Market Overview
6.6.2 Hospital Pharmacies
6.6.3 Drug Store & Retail Pharmacies
6.6.4 Online Pharmacies
6.7 Latin America Anti-Obesity Drugs Market (2017-2032) by Countries
6.7.1 Market Overview
6.7.2 Brazil
6.7.3 Argentina
6.7.4 Mexico
6.7.5 Others
7 Brazil Anti-Obesity Drugs Market (2017-2032)
7.1 Brazil Anti-Obesity Drugs Market (2017-2032) by Drugs
7.1.1 Market Overview
7.1.2 Semaglutide
7.1.3 Phentermine/Topiramate
7.1.4 Naltrexone/Bupropion
7.1.5 Liraglutide
7.1.6 Gelesis 100
7.1.7 Orlistat
7.1.8 Phentermine
7.1.9 Methamphetamine
7.1.10 Tirzepatide
7.2 Brazil Anti-Obesity Drugs Market (2017-2032) by Drug Class
7.2.1 Market Overview
7.2.2 Amphetamine
7.2.3 GLP-1 receptor agonist
7.2.4 Lipase Inhibitor
7.3 Brazil Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
7.3.1 Market Overview
7.3.2 Centrally Acting Drugs
7.3.3 Peripherally Acting Drugs
7.4 Brazil Anti-Obesity Drugs Market (2017-2032) by Route of Administration
7.4.1 Market Overview
7.4.2 Oral
7.4.3 Subcutaneous
7.5 Brazil Anti-Obesity Drugs Market (2017-2032) by Prescription Type
7.5.1 Market Overview
7.5.2 Prescription Drugs
7.5.3 Over The Counter Drugs
7.6 Brazil Anti-Obesity Drugs Market (2017-2032) by Distribution Channel
7.6.1 Market Overview
7.6.2 Hospital Pharmacies
7.6.3 Drug Store & Retail Pharmacies
7.6.4 Online Pharmacies
8 Argentina Anti-Obesity Drugs Market (2017-2032)
8.1 Argentina Anti-Obesity Drugs Market (2017-2032) by Drugs
8.1.1 Market Overview
8.1.2 Semaglutide
8.1.3 Phentermine/Topiramate
8.1.4 Naltrexone/Bupropion
8.1.5 Liraglutide
8.1.6 Gelesis 100
8.1.7 Orlistat
8.1.8 Phentermine
8.1.9 Methamphetamine
8.1.10 Tirzepatide
8.2 Argentina Anti-Obesity Drugs Market (2017-2032) by Drug Class
8.2.1 Market Overview
8.2.2 Amphetamine
8.2.3 GLP-1 receptor agonist
8.2.4 Lipase Inhibitor
8.3 Argentina Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
8.3.1 Market Overview
8.3.2 Centrally Acting Drugs
8.3.3 Peripherally Acting Drugs
8.4 Argentina Anti-Obesity Drugs Market (2017-2032) by Route of Administration
8.4.1 Market Overview
8.4.2 Oral
8.4.3 Subcutaneous
8.5 Argentina Anti-Obesity Drugs Market (2017-2032) by Prescription Type
8.5.1 Market Overview
8.5.2 Prescription Drugs
8.5.3 Over The Counter Drugs
8.6 Argentina Anti-Obesity Drugs Market (2017-2032) by Distribution Channel
8.6.1 Market Overview
8.6.2 Hospital Pharmacies
8.6.3 Drug Store & Retail Pharmacies
8.6.4 Online Pharmacies
9 Mexico Anti-Obesity Drugs Market (2017-2032)
9.1 Mexico Anti-Obesity Drugs Market (2017-2032) by Drugs
9.1.1 Market Overview
9.1.2 Semaglutide
9.1.3 Phentermine/Topiramate
9.1.4 Naltrexone/Bupropion
9.1.5 Liraglutide
9.1.6 Gelesis 100
9.1.7 Orlistat
9.1.8 Phentermine
9.1.9 Methamphetamine
9.1.10 Tirzepatide
9.2 Mexico Anti-Obesity Drugs Market (2017-2032) by Drug Class
9.2.1 Market Overview
9.2.2 Amphetamine
9.2.3 GLP-1 receptor agonist
9.2.4 Lipase Inhibitor
9.3 Mexico Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
9.3.1 Market Overview
9.3.2 Centrally Acting Drugs
9.3.3 Peripherally Acting Drugs
9.4 Mexico Anti-Obesity Drugs Market (2017-2032) by Route of Administration
9.4.1 Market Overview
9.4.2 Oral
9.4.3 Subcutaneous
9.5 Mexico Anti-Obesity Drugs Market (2017-2032) by Prescription Type
9.5.1 Market Overview
9.5.2 Prescription Drugs
9.5.3 Over The Counter Drugs
9.6 Mexico Anti-Obesity Drugs Market (2017-2032) By Distribution Channel
9.6.1 Market Overview
9.6.2 Hospital Pharmacies
9.6.3 Drug Store & Retail Pharmacies
9.6.4 Online Pharmacies
10 Regulatory Framework
11 Patent Analysis
11.1 Analysis by Type of Patent
11.2 Analysis by Publication year
11.3 Analysis by Issuing Authority
11.4 Analysis by Patent Age
11.5 Analysis by CPC Analysis
11.6 Analysis by Patent Valuation
11.7 Analysis by Key Players
12 Funding and Investment Analysis
12.1 Analysis by Funding Instances
12.2 Analysis by Type of Funding
12.3 Analysis by Funding Amount
12.4 Analysis by Leading Players
12.5 Analysis by Leading Investors
12.6 Analysis by Geography
13 Partnership and Collaborations Analysis
13.1 Analysis by Partnership Instances
13.2 Analysis by Type of Partnership
13.3 Analysis by Leading Players
13.4 Analysis by Geography
14 Supplier Landscape
14.1 Market Share by Top 5 Companies
14.2 VIVUS Inc
14.2.1 Financial Analysis
14.2.2 Product Portfolio
14.2.3 Demographic Reach and Achievements
14.2.4 Mergers and Acquisitions
14.2.5 Certifications
14.3 Pfizer, Inc.
14.3.1 Financial Analysis
14.3.2 Product Portfolio
14.3.3 Demographic Reach and Achievements
14.3.4 Mergers and Acquisitions
14.3.5 Certifications
14.4 Novo Nordisk
14.4.1 Financial Analysis
14.4.2 Product Portfolio
14.4.3 Demographic Reach and Achievements
14.4.4 Mergers and Acquisitions
14.4.5 Certifications
14.5 Bayer AG
14.5.1 Financial Analysis
14.5.2 Product Portfolio
14.5.3 Demographic Reach and Achievements
14.5.4 Mergers and Acquisitions
14.5.5 Certifications
14.6 F Hoffmann-La Roche
14.6.1 Financial Analysis
14.6.2 Product Portfolio
14.6.3 Demographic Reach and Achievements
14.6.4 Mergers and Acquisitions
14.6.5 Certifications
14.7 Glaxosmithkline
14.7.1 Financial Analysis
14.7.2 Product Portfolio
14.7.3 Demographic Reach and Achievements
14.7.4 Mergers and Acquisitions
14.7.5 Certifications
14.8 Arena Pharmaceuticals
14.8.1 Financial Analysis
14.8.2 Product Portfolio
14.8.3 Demographic Reach and Achievements
14.8.4 Mergers and Acquisitions
14.8.5 Certifications
14.9 Eisai Co. Ltd
14.9.1 Financial Analysis
14.9.2 Product Portfolio
14.9.3 Demographic Reach and Achievements
14.9.4 Mergers and Acquisitions
14.9.5 Certifications
14.10 Takeda Pharmaceutical Company
14.10.1 Financial Analysis
14.10.2 Product Portfolio
14.10.3 Demographic Reach and Achievements
14.10.4 Mergers and Acquisitions
14.10.5 Certifications
14.11 Nalpropion Pharmaceuticals Inc
14.11.1 Financial Analysis
14.11.2 Product Portfolio
14.11.3 Demographic Reach and Achievements
14.11.4 Mergers and Acquisitions
14.11.5 Certifications
15 Latin America Anti-Obesity Drugs Market – Distribution Model (Additional Insight)
15.1 Overview
15.2 Potential Distributors
15.3 Key Parameters for Distribution Partner Assessment
16 Key Opinion Leaders (KOL) Insights (Additional Insight)
17 Company Competitiveness Analysis (Additional Insight)
17.1 Very Small Companies
17.2 Small Companies
17.3 Mid-Sized Companies
17.4 Large Companies
17.5 Very Large Companies
18 Payment Methods (Additional Insight)
18.1 Government Funded
18.2 Private Insurance
18.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The Latin America anti-obesity drugs market is expected to be driven by the rising demand for the global market, which is anticipated to grow at a CAGR of 10.7% during the forecast period of 2024-2032, to reach a market value of USD 6.3 billion by 2032.
Major factors aiding the market demand include the increasing prevalence of obesity along with diabetes mellitus among all age groups.
One of the significant trends in the market is the increasing research and development activities and regulatory approvals to reduce the number of obese patients in the region. For instance, the approval of tesofensine by Mexican regulatory authorities for the treatment of obese patients.
Based on drugs, the market is segmented into Semaglutide, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide, Gelesis 100, Orlistat, Phentermine, Methamphetamine, and Tirzepatide.
It includes amphetamines, GLP-1 receptor agonists, and lipase inhibitors.
Mechanisms of action include centrally acting drugs and peripherally acting drugs.
Route of administration includes oral and subcutaneous.
Type of prescriptions include prescription drugs and over-the-counter drugs.
Based on distribution channels, the market is segmented into hospital pharmacies, drug store & retail pharmacies, and online pharmacies.
The market segmentation by countries includes Brazil, Argentina, Mexico, and others
The key players in the market are and VIVUS Inc., Nalpropion Pharmaceuticals Inc., Pfizer, Inc., Novo Nordisk, Bayer AG, F Hoffmann-La-Roche, GlaxoSmithKline, Arena Pharmaceuticals, Eisai Co. Ltd, Takeda Pharmaceutical Company.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2639
$2399
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 4399
$3999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 5829
$5299
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 6929
$6299
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER